RSNOs (S-nitrosothiols) regulate platelet and megakaryocyte function, and may act in vivo as a nitric oxide reservoir. There is a discrepancy between the spontaneous rate of NO release from different RSNO compounds and their pharmacological effects, implying that target cells may mediate biological activity either by metabolism of RSNOs or by displaying cell surface receptors. In the present study, we sought evidence for rapid cell-mediated metabolism of RSNOs. Exposure of platelets to GSNO (S-nitrosoglutathione) for as little as 5 s inhibited thrombin-induced platelet aggregation by >95%; however, AlbSNO (Snitrosoalbumin) was much less effective over these short time periods. Incubation of 1 µM GSNO or AlbSNO with platelets and megakaryocytes resulted in a 25-34% loss of RSNO recoverable from the supernatant (P < 0.02) within 30 s. This rapid cell-mediated RSNO decay did not progress further over 5 min, and could not be accounted for by release of free NO. The γ-glutamyl transpeptidase inhibitor acivicin (100 µM) partially decreased GSNO decay, whereas the membrane-impermeable thiol-blocking agent 5,5 -dithiobis-(2-nitrobenzoic acid) (100 µM) completely blocked cell-mediated GSNO decay and partially blocked AlbSNO decay. Our results highlight differences between high-and low-molecular-mass RSNOs with regard to their rapid metabolism/uptake and subsequent cellular responses, and indicate a critical role for extracellular thiols in RSNO metabolism by platelets and megakaryocytes.
Introduction
Nitric oxide is an important regulator of platelet and megakaryocyte function. RSNOs (S-nitrosothiols; formed by the nitrosation of thiol groups) possess NO-related biological activity and may constitute an endogenous reservoir of stored NO [1] .
RSNOs are detected in vivo at nanomolar concentrations, and include both high-molecular-mass [e.g. AlbSNO (Snitrosoalbumin), S-nitrosohaemoglobin] and low-molecularmass [e.g. S-nitrosocysteine, GSNO (S-nitrosoglutathione)] forms. RSNOs are potentially useful as therapeutic agents, e.g. GSNO has been shown to inhibit platelet aggregation without altering vascular tone, implying a platelet-selective action [2] . The mechanism of this selectivity is not yet understood. Recent evidence indicates that GSNO also regulates megakaryocyte apoptosis and platelet production [3] .
Current concepts of RSNO chemistry do not explain their ability to transfer NO into responding cells [4] . Possible mechanisms include transmembrane diffusion of released NO or transfer of nitroso groups on to receptor thiols via a process of transnitrosation.
A variety of enzymes, such as γ-GT (γ-glutamyl transpeptidase), are reported to catalyse GSNO decay [5] , and both protein disulphide isomerase [6] and glutathione peroxidase Key words: cell surface thiol, γ-glutamyl transpeptidase, megakaryocyte, nitric oxide, Snitrosothiol, platelet. Abbreviations used: AlbSNO, S-nitrosoalbumin; DTNB, 5,5 -dithiobis-(2-nitrobenzoic acid); GSNO, S-nitrosoglutathione; γ-GT, γ-glutamyl transpeptidase; HBS, Hepes-buffered saline; RSNO, S-nitrosothiol. 1 To whom correspondence should be addressed (e-mail m.p.gordge@wmin.ac.uk). [7] can catalyse transnitrosation. This may be important in RSNO signalling, because the kinetics of spontaneous transnitrosation do not favour rapid NO transfer [8] .
Previous studies have demonstrated cell-mediated metabolism of RSNOs, but at supraphysiological concentrations and over long time periods [9, 10] , whereas RSNO signalling occurs rapidly. In the present study, an attempt was made to investigate the metabolism of RSNOs by platelets and megakaryocytes at relatively low concentration and over short time periods by monitoring the cell-mediated decay of GSNO and AlbSNO (both at 1 µM) occurring within the first 5 min of exposure.
Materials and methods

Preparation of RSNOs
GSNO and S-nitrosocysteine were prepared by incubation of glutathione or cysteine respectively with acidified sodium nitrite and quantification by absorbance at 334 nm using molar absorption coefficients of 0.85 and 0.74 mM
respectively. AlbSNO was prepared by incubation of human serum albumin with S-nitrosocysteine to bring about transfer of the nitroso group, followed by separation on Sephadex G-25. AlbSNO was then quantified by reference to a GSNO calibration curve.
RSNO measurement
RSNO was quantified by measuring Cu + -catalysed NO release using a Clark-type NO electrode (World Precision Instruments, Stevenage, U.K.) as described by Pfeiffer et al. [11] . The assay was calibrated for each experiment using GSNO or AlbSNO, as appropriate, and was linear over the concentration range 250-2000 nM, with intra-assay values for a coefficient of variation of 5% or less.
Cell culture
The human megakaryocyte cell line MEG-01 was grown in RPMI-1640 medium containing 10% (v/v) foetal bovine serum. Medium was replaced every 4 days and cells were washed and resuspended in HBS (Hepes-buffered saline, pH 7.3) at a count of 3 × 10 9 cells/l for experiments.
Platelet aggregation
Washed human platelets were prepared and suspended in HBS at a count of 200 × 10 9 cells/l. Platelet aggregation was induced with human thrombin (0.1 unit/ml) and monitored turbidometrically.
Cell-mediated RSNO metabolism experiments
RSNO was incubated in the presence or absence of platelets or megakaryocytes for various time periods to allow cellmediated metabolism to occur. Cells were then removed by rapid centrifugation, and residual RSNO in the supernatant was measured as described above. Separation of supernatant from cells was achieved within a maximum processing time of 30 s. In further experiments, spontaneous release of free NO following addition of RSNO to cells was measured using the NO electrode. The effect on RSNO metabolism of inhibiting γ-GT was investigated by incubating cells for 30 min with acivicin (100 µM), prior to addition of RSNO. Similarly, the role of exofacial membrane thiols was investigated using the membrane-impermeant thiol blocking agent DTNB [5,5 -dithiobis-(2-nitrobenzoic acid)] at 100 µM.
Results
Pre-incubation of 1 µM GSNO with platelets for as little as 5 s resulted in >95% inhibition of thrombin-induced aggregation, whereas AlbSNO at a similar concentration produced only 10% inhibition. Incubation of GSNO or AlbSNO (both 1 µM) with washed platelets or MEG-01 cells led to a 25-34% loss of RSNO compared with the buffer control (P < 0.02). RSNO removal occurred within 30 s, but did not progress further over 5 min (Figure 1) . Only 20-25% of cell-mediated RSNO loss could be accounted for by release of free NO (measured using NO electrode). γ-GT inhibition by acivicin partially blocked GSNO decay, but modification of extracellular thiol groups with DTNB inhibited the cell-mediated metabolism of both GSNO and AlbSNO (Figure 2 ).
Discussion
Our results show a rapid decay of RSNO mediated by platelets and megakaryocytes at pathophysiologically relevant RSNO concentrations, suggesting that the anti-platelet activity of RSNOs may be associated with cell-mediated uptake or metabolism. This loss of RSNO was not fully accounted for by release of free NO into the supernatant, indicating that RSNO compounds must interact directly with platelets and megakaryocytes to bring about physiological responses. These results are consistent with earlier evidence that the bioactivity of RSNO compounds is not explained by their release of free NO [12] . Differences shown between GSNO and AlbSNO in their anti-platelet activity and in the effects of acivicin and DTNB on their metabolism may reflect the previously reported requirement of AlbSNO to be 'activated' by low-molecular-mass thiols prior to intraplatelet NO delivery [13] .
GSNO is a substrate for γ-GT (K m 28 µM) [5] ; however, inhibition of γ-GT by acivicin failed to block cell-mediated GSNO decay completely and had no effect on AlbSNO decay, suggesting only a partial role of this enzyme in rapid RSNO metabolism. On the other hand, modification of extracellular thiols with membrane-impermeant DTNB completely abolished cell-mediated GSNO decay and also partially inhibited AlbSNO decay. This supports the concept of RSNO signalling via transfer of nitroso groups from RSNO donors to exofacial thiols. Suggested targets on the platelet surface include protein disulphide isomerase [14] and integrin αIIbβ3 [15] . Further work is required to define the role of these and other RSNO 'receptor' thiols on the cell surface, as well as the redox events controlling their display, maintenance and regeneration following RSNO engagement.
RSNOs are potent and selective anti-platelet agents, which have shown therapeutic usefulness in a number of clinical studies. Understanding the mechanism of nitroso group transfer into responding cells will be necessary in order to maximize their therapeutic usefulness and to facilitate the development of novel therapeutic strategies in vascular disease.
